ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
54 announcements
Sun Pharmaceutical Industries Ltd reported revenue from operations of ₹14,612 Cr (+12.8% YoY) and net profit of ₹2,714 Cr (+26.2% YoY) for Q4 FY26.
Sun Pharma reported FY26 consolidated revenue of ₹58,220.11 Crore with a 11.9% growth. The board recommended a final dividend of ₹5 per share for the year.
Sun Pharmaceutical Industries Ltd reported revenue from operations of ₹14,612 Cr (+12.8% YoY) and net profit of ₹2,724 Cr (+26.1% YoY) for Q4 FY26.
Sun Pharma approved audited FY26 results and recommended a final dividend of Rs. 5 per share. Consolidated sales reached ₹58,462.04 Crore, marking 11.9% year-on-year growth.
Sun Pharma received requests from three promoter group members to reclassify 4,31,75,371 shares to the public category. The board will examine these requests in due course.
Sun Pharmaceutical appointed Dr. Andreas Eugen Busch as an Independent Director for five years. His extensive global R&D expertise will strengthen the board's drug discovery leadership.
Sun Pharmaceutical appointed Dr. Andreas Busch as Independent Director for five years. Ms. Rama Bijapurkar retires, and Ms. Satyavati Berera joins key committees.
Sun Pharmaceutical Industries scheduled a board meeting for May 22, 2026. The board will consider audited FY26 results and a final dividend recommendation.
Sun Pharmaceutical shareholders approved the appointment of Ms. Satyavati Berera as Independent Director via postal ballot. The five-year term is effective from May 08, 2026.
Sun Pharmaceutical Industries Limited announced that CRISIL and ICRA reaffirmed its 'AAA' and 'A1+' ratings. CRISIL placed the long-term rating on 'Watch with Developing Implications' following Sun Pharma's agreement to acquire Organon & Co.
Sun Pharma announced the acquisition of Organon & Company for an enterprise value of $11.75 billion (approx. ₹1,11,625 Crore). The deal expands Sun's footprint in women's health and biosimilars across 140 countries, including a significant entry into China. The transaction is expected to close in six to nine months and be EPS accretive from the first year.
Sun Pharma announces the acquisition of Organon & Company for $11.75bn Enterprise Value ($14/share), targeting leadership in women's health and a major expansion in China.
Sun Pharmaceutical's US subsidiary will acquire 100% of Organon & Co. for ₹37,649 Crore ($3.99B equity value) in an all-cash merger. The deal, valued at $11.75B enterprise value, strengthens Sun's global portfolio in women's health and biosimilars. Completion is expected in early 2027, subject to regulatory and shareholder approvals.
Sun Pharma scales into global specialty dominance by acquiring Organon for $11.75 billion. The deal pivots the portfolio toward high-margin Women's Health and Biosimilars while adding significant China footprint.
Sun Pharma has agreed to acquire 100% of Organon & Co. for US$ 14.00 per share in an all-cash deal valued at ₹110,450 Crore (EV). The acquisition marks Sun Pharma's entry into biosimilars and significantly expands its global Women's Health portfolio. The transaction is expected to close in early 2027.
Sun Pharma announces the acquisition of Organon & Co. for $14.0 per share ($11.75Bn EV), creating a global entity with ~$12.4Bn revenue.
Sun Pharmaceutical Industries Limited incorporated a new 100% subsidiary, Sun Pharma America, Inc., in the USA on April 23, 2026. The entity belongs to the pharmaceutical industry and was established for internal group structuring purposes through initial cash consideration.
Sun Pharmaceutical Industries Limited announced the conclusion of its postal ballot. Shareholders approved resolutions regarding the ratification of Cost Auditor remuneration for FY 2025–26, alterations to the Memorandum of Association, and the re-appointment of Dr. Pawan Goenka as an Independent Director for a five-year term starting May 2026.
Sun Pharmaceutical Industries clarified that news regarding a potential $12 billion deal with Organon is speculative. The company stated there is no material information requiring disclosure under Regulation 30. Sun Pharma maintains high governance standards and will inform exchanges of any future material events as required.
Sun Pharmaceutical Industries Limited has initiated a postal ballot to seek shareholder approval for the appointment of Ms. Satyavati Berera as an Independent Director. Her proposed five-year tenure begins on May 8, 2026. The voting period concludes on May 8, 2026, marking a key corporate governance update for the company.
Sun Pharmaceutical Industries Limited is conducting a postal ballot to seek shareholder approval for appointing Ms. Satyavati Berera as an Independent Director for a five-year term. The e-voting period runs from April 9 to May 8, 2026. This appointment aims to maintain gender diversity and strengthen board oversight with her financial and risk expertise.
Sun Pharmaceutical Industries Ltd submitted its quarterly confirmation certificate for the period ended March 31, 2026, regarding the dematerialisation of securities. The registrar, MUFG Intime India, confirmed compliance with SEBI (Depositories and Participants) Regulations. This is a routine administrative filing with no material impact on business operations.
Sun Pharmaceutical Industries has appointed Ms. Satyavati Berera as a Non-Executive Independent Director for a five-year term effective May 8, 2026. Ms. Berera, a former COO of PwC India and a Chartered Accountant, brings over 40 years of experience in governance, risk, and operations to the board.
Sun Pharmaceutical Industries has appointed Ms. Satyavati Berera as an Independent Director for a five-year term, subject to shareholder approval. Ms. Berera, a former COO of PwC India, brings extensive expertise in governance, risk, and compliance. This appointment aims to strengthen the Board's independence and oversight capabilities.